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HLA-D, DR—CLINICAL SIGNIFICANCE
Α New Strategy to Improve Kidney Graft Survival:
The Induction of CML Nonresponsiveness
J J. van Rood, G. G. Persijn, A. van Leeuwen, E. Goulmy, and Β W. Gabb
Α LTHOUGH immunosuppression made
*"*· renal allografting possible, the excellent
results in ABO-compatible HLA-identical
siblings showed that optimal matching
allowed the immunosuppressive dosage to be
significantly reduced. Attempts to extrapo-
late the sibling findings to unrelated donor-
recipient pairs have until recently met with
only partial success, however.
During the last half year evidence has been
presented by several teams that matching for
HLA-DR determinants correlates to an
unprecedented level with improved renal allo-
graft prognosis between unrelated donor-
recipient pairs.
Although the effectiveness of HLA-DR
matching is certainly the most exciting new
data, it is equally certain that it is not the only
factor influencing renal graft survival. It is
impossible to give here an all encompassing
and complete review. For that reason we have
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selected a few topics that we think are of most
interest. We will divide this review into three
parts: past, present, and future.
THE PAST
Everybody agrees that a positive cross-
match leads in most instances to graft rejee-
tion. Studies by Thomas et al. and Stiller et
al. suggest that both lymphocyte-dependent
antibody and cytolytic cells can precede graft
rejeetion.li2 The point we want to stress here is
that very little is known about the speeificity
of these antibodies and cytolytic cells. They
have so far been presumed to have anti-
HLA-A and Β and possibly C speeificity, but
other Systems in and outside HLA are almost
certainly involved as well. This is illustrated
by the following: Α woman who had had three
pregnancies reeeived one blood transfusion
and formed a strong anti-Cw4. She was trans-
planted with an HLA-A, B, and C-identical
kidney. Although the crossmatch had been
negative, the graft was rejeeted within a
week. Further analysis of the pretransplant
serum revealed the presence of an anti-HLA-
DRw6 antibody that had not been detected in
the crossmatch. The kidney donor was DRw6
positive. The findings thus lrnply that the DR
antigens can be targets that if attacked by an
antibody can lead to graft rejeetion. Further-
more, Conleth and Stastny found that DR
antigens can also bc a target in the CML
test3 These examples emphasize that it is
technically fcasible to determine the speeific-
ity not only of the recipient's antibodies but
possibly also of his lympholytic cells. It should
be emphasi7ed that one cannot rely solely on a
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crossmatch because it is well known that
false-negative or so-called CYNAP reactions
can occur. The Situation is thus strikingly
similar to that of blood transfusion.
The conclusion from this is clear: Α cross-
match should always be performed. Further-
more, if the effects of preexisting immunity
are to be avoided, it is essential that the
specificity of antibodies formed by the
patients be determined as carefully as possi-
ble. In addition, the better the match between
donor and recipient for the HLA-A and Β
antigens, the smaller will be the chance that
missed anti-HLA-A or Β antibodies can
cause graft rejection.
This brings us to HLA matching in cadav-
eric renal transplantation. It has taken us a
long time, but finally those who agree that
HLA-A and Β matching can improve renal
graft survival outnumber those who think it
does not—on both sides of the Atlantic.
One could summarize the Situation by
saying that matching for HLA-A and Β
matching significantly, although not impres-
sively, improves graft survival (10%-20%
between best and poorly matched grafts).
This improvement is probably due both to the
importance of these antigens as targets in the
homograft reaction and to the fact that they
are in linkage disequilibrium with the
HLA-D and DR determinants.
Next we would like to draw attention to the
two-faced role of blood transfusion in trans-
plantation. Opelz et al. were the first to
present significant evidence that blood trans-
fusion not only can cause immunization,
which endangers graft survival, but can also
prolong graft survival:4 van Es and Bainer
produced experimental evidence for this in
the rhesus rnonkey.5 We want to stress in this
connection two important points from our
own work. The first is that we have confirmed
in a prospective study our previous finding
that a single transfusion improves graft
survival;6 17 nontransfused patients received
a Single washed (i.e., buffy coat poor) blood
transfusion before transplantation, and of
these only three transplants failed for nonim-
munologic reasons (one with coronary occlu-
sion and two with viral pneumonia). The
second, and this was a new finding, was that 7
of the 8 patients who received blood made
completely free of buffy coat cells by passing
it through a cotton wool filter7 rejected their
kidney. These results were as poor as when no
transfusions were given.6 Thus for graft
protection one needed the equivalent of about
50 ml of allogeneic ACD blood. Although not
randomized, this was a prospective study.
Since only one blood transfusion was given, it
was difficult to imagine an immunogenetic
System that would allow for graft protection
in such a large part of the patients mediated
by specific alloantibodies, and it thus seemed
very unlikely that enhancing antibodies were
responsible for graft protection. One alterna-
tive possibility was that it was due to the
induction of a relatively nonspecific suppres-
sor mechanism.
THE PRESENT
An oft-repeated question has been that if
HLA matching is important, why do some
HLA-A and/or B-mismatched grafts do so
well? An answer to this question is provided
by the observation that graft survival is signif-
icantly improved by HLA-DR matching even
in the face of mismatches for HLA-A and/or
B8-l.
HLA-DR antigens can be recognized sero-
logically on Β cells.12"15 They are probably not
identical to the HLA-D determinants that
stimulate in the MLC test but are very closely
linked to them. Thus in Northwest Europe by
typing and matching for HLA-DR one can
match for HLA-D. In order to assess its
importance in kidney transplantation, HLA-
DR matching was performed retrospectively
on peripheral blood cells of the recipients and
frozen spieen cells of the kidney donors. Of
the few recipients who had died after trans-
plantation, frozen cells were available. Table
1 shows that not only HLA-DR-identical
combinations but also combinations where
only one HLA-DR determinant was shared
showed good graft survival." Other groups in
tfk
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Table 1. Number of Eurotransplant Patients in the
Various HLA-A, B, and DR-match Classifications
Α and Β Loci
Combined
No of Antigens
Mismatched
0
1
2
3
4
Totais
DR Locus No of
Antigens Mismatched
0
—
3/-
1/2
1 / -
—
5/2
1
10/2
16/2
7/4
1 / -
—
34/8
2
3/1
5/5
4/8
2/1
1 / -
15/15
Totais
13/3
24/7
12/14
4/1
1 / -
54/25
Slash indicates functioning/nonfunctiomng grafts as of
begmning of April 1978 (Adapted from Persijn et al " )
Europe have done similar studies and have
published comparable data16"18 (Table 2). In
all series there was a striking improvement of
graft survival by matching for one HLA-DR
determinant in comparison to the group with
two HLA-DR determinants mismatched. The
improvement by matching for two HLA-DR
determinants was expected, since earlier stud-
ies had shown that a low or negative MLC
test between parent-child or unrelated donor-
recipient pairs improved graft survival.'9"2'
Not all HLA-D or DR-identical combina-
tions lead to a negative or low MLC test, but
many do,22 and this could explain the good
results in the full-house-identical group.
On the other hand, combinations that share
only one HLA-DR determinant are always
MLC positive. Why is it, then, that grafts
mismatched for one HLA-DR antigen do so
well? From the point of immunogenetics, this
is, of course, heresy: a difference of an antigen
between donor and recipient has always been
considered to be dominant over sharing an
antigen. There exists corroborating evidence
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in the parent-child data. They, too, share one
DR determinant and do much better than
those differing by two; in fact in Holland they
do as well as HLA-identical siblings (Persijn
GG: Unpublished observations).
Similarly, matching for an Α and Β antigen
combination such as A1-B8 and A3-B7,
which are in streng linkage disequilibrium
with a DR antigen, improved graft survival
between unrelated individuals. The improve-
ment was greater than was found if just any
two HLA-A and Β antigens were shared.
Thus in this Situation donor and recipient
were matched indirectly for one DR anti-
gen.23
From these independent lines of evidence,
it is safe to conclude that matching for just
one DR determinant can significantly im-
prove graft survival. It is also clear that the
limited data available are in part retrospec-
tive, and prospective trials are indicated.
It should be stressed that all donors in this
study who received a kidney matched for one
DR determinant had been transfused. We
think that this is an important prerequisite,
since not all donor-recipient combinations in
this group do well.
Swedish workers found that graft survival
in parent-child combinations was good only if
the recipient had been transfused before
transplantation.17 The Dutch data tend to
agree with this, although a control group of
nontransfused recipients is lacking. These
data, then, suggest the following:
(1) Matching for one HLA-DR determi-
nant in parent-child combinations and, by
inference, in the unrelated combinations leads
Table 2 DR Matching in Europe (Functional "/Total)
Eurotransplant"
Geneva'0
Oslo9
Oxford8
Total
Zero DR
Mismatches
6/7
0/0
2/2
4 / 4
12/13
(92%)
Ρ
= 0 60
One DR
Mismatch
37/42
22/25
15/24
32/40
106/131
(81%)
Ρ
= 0 0002
Two DR
Mismatches
18/30
12/23
14/31
27/40
71/124
(57%)
" At 6 months after transplantation
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to significant improvements, providing that
the recipient had been transfused before
transplantation. This conclusion is of a
preliminary nature because Solheim et al. did
not find a graft-protecting effect of blood
transfusions in parent-child combinations.18
(2) DR serology is sufficiently accurate to
select unrelated individuals who are matched
for one DR determinant.
(3) The effect of matching for one DR
determinant overrides the effect of incompati-
bility for multiple other determinants both in
and outside HLA. It should, however, be
emphasized that compatibility for Α and Β
reinforces the effect on one DR match." We
cannot, of course, yet exclude the possibility
that it is not DR that we should match for but
another closely linked locus, e.g., HLA-D.
Interracial transplants will be very useful in
evaluating this.24
In an attempt to clarify the mechanism by
which matching for one DR determinant
overrides the effect of incompatibility of other
antigens, we investigated whether or not these
findings on DR matching and graft survival
had an in vitro correlate. Both MLC and
CML tests (after in vitro priming) were
studied. Lymphocytes were taken from
patients 3-18 months after transplantation,
and these were reacted with the splenocytes,
which had been stored in liquid nitrogen, from
their specific kidney donor. Four patients had
rejected their graft, while seven had good-
functioning grafts as expected. All MLC tests
100
cytolysis
were positive. The CML findings, which can
be regarded as a measure of cellular immu-
nity in vitro, are shown in Figure 1. The
lymphocytes of the four patients who had
rejected their graft all reacted strongly in the
MLC test after in vitro priming with the
splenocytes of their specific donor (and with
lymphocytes from other individuals) indepen-
dently of their DR match. In contrast, the
lymphocytes of four patients who had func-
tioning grafts and who also shared one DR
determinant with the donor had a negative
CML test with their specific donor. This low
reactivity was specific. since their lympho-
cytes lysed the lymphocytes of donors selected
at random. Of the other three patients with
functioning grafts, two differed for two DR
determinants and one was DR identical to
their respective donors. All three reacted
about equally strongly with both the specific
donors and randomly selected cells. This is, of
course, a very limited set of data, but it is
reassuring that we could actually show that
the CML test changed from positive before
transplantation to negative (as shown here)
after transplantation. So far we have found
CML nonreactivity only in the one DR anti-
gen-matched group, but it is, of course, quite
possible that more extensive studies will show
that nonreactivity can also occur in either the
two antigen-matched or mismatched group.
These preliminary findings show striking
similarity to observations of Thomas et al.,25
who studied CML reactivity in parent-child
specific donor-
R· rejection !
F· functioning
randomly
selected
donor
1 7
I I
Fig. 1. CML reactivity after transplanta-
tion and DR matching.
number of DR mismatches
NB non-responsiveness is specific
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combinations, and Woningeit and Pichl-
mayr,26 who studied cadaveric kidney trans-
plant recipients. The new data presented here
show that CML nonreactivily is found a few
months and not many years after transplanta-
tion and that to improve graft survival
previous blood transfusions appear to be
necessary. Furthermore, under these condi-
tions matching by DR serology in unrelated
donor-recipient combinations appears to be as
effective as matching by haplotype in the
related parent-child combinations. The most
important new finding is, of course, that for
the first time CML unresponsiveness has been
shown to correlate with the sharing of one DR
determinant between donor and recipient.
Small as the data base is, it is significant
(p = 0.03, Fisher's exact test).
In summary, the current picture emerges
as follows:
(1) Matching not only for two but also for
one DR determinant improves graft survival
to about 80% at 1 year. We should like to
reiterate that our data indicate also that
partial matching for HLA-A and Β will
improve results further to about 90%, i.e.,
equal to that of HLA-identical siblings."
Thus DR matching reinforces but does not
replace HLA-A and Β matching.
(2) Donor-specific CML nonreactivity
develops in at least some of the patients who
share one DR determinant with the donor.
This nonreactivity is possibly due to the
induetion of a suppressor cel].25
(3) Previous blood transfusions, which
might induce partial aspeeifie tolerance and
immunosuppression appear to be necessary.
THE FUTURE
In the first place, the implications of
donor-specific CML nonreactivity will have
to be studied further. On the practical level, if
current trends hold up it might be possible in
the immediate future to improve renal allo-
graft survival results to 80% or 90% at 1 year.
Because partial DR matching resuits in excei-
lent graft survival and because of the appar-
ent restricted polymorphism of the DR locus,
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recipient pools of a few hundred persons
might be sufficient to find adequately
matched recipients for the majority of donor
kidneys. This contrasts favorably with the
pools of thousands of recipients now in use
that enable one to realize only 10%—20%
HLA-A and B-identical matches. This might
be true not only for renal but also for other
tissue transplants, including hearts.
The biomedical implications might be even
more impressive. It seems that we have stum-
bled on a relatively simple strategy to induce
donor-specific nonresponsiveness to MHC
determinants and possibly other antigens as
well as measured in the CML test. All that
appears necessary is a single blood transfu-
sion, a one DR antigen-matched kidney graft,
and Standard immunosuppression. The mech-
anism by which this can be done is as yet
undefined but might well be the induetion of
suppressor cells.25 The one DR-matched graft
that does so well should be compared with the
two DR-matched graft, which appears to do
at least equally well. The central question
here is whether they represent the same or
different mechanisms that allow good graft
survival.
The role of blood transfusion and immuno-
suppression needs in this context to be further
analyzed. It would be of interest to investigate
if there exists a link between blood transfu-
sion, the appearance of cold Β cell antibodies,
and graft protection. The immunogenetic
requirements, apart from a shared DR deter-
minant, should be studied, especially the
question of whether or not a dual recognition
phenomenon between DR and the equivalent
of the H2-IJ locus plays a role. Additionally,
findings discussed above might perhaps be of
importance in the management of autoim-
mune diseases (restoration of tolerance to
self-antigens) and even of malignancies. It
will also bc of interest to determine if, and
how, thesc findings apply also to fetal-mater-
nal tolerance and, if so, whether or not a
similar rationale can be used in the treatment
of habitual abortion.
To return to the topic of this Conference, it
INDUCTION OF CML NONRESPONSIVENESS 741
appears to be justified to investigate whether
or not pretreatment of the donor of a bone
marrow graft with a blood transfusion and
immunosuppression will diminish graft-
versus-host reaction in MHC-identical com-
binations or might even make it possible to
use HLA haploidentical donors. Of course,
this should be first tested in animals, by
preference in rhesus monkeys.
Α related question also requires urgent
answers: Is it really true that Β cell antibodies
that react primarily at ± 4°C are protective,
while those with their Optimum at 37°C can
actually härm the graft?27·28
Although matching for DR will be the
main topic of interest, other factors influenc-
ing graft survival should not be overlooked.
There seems little doubt that monocyte anti-
bodies, which appear to react with antigens on
endothelial cells as well, can cause graft
rejection.29·30 Finally, the role of incompatibü-
ity for the Lewis blood group system should
be evaluated by other groups in addition to
the French, who noticed it first.31
We think personally that in the future the
central question will be whether the recipient
has been immunized or not, not only against
the HLA-A, B, and C antigens but also
against other antigens such as the DR anti-
gens, the monocyte antigens, and possibly
Lewis antigens. If the recipient has not been
immunized against these antigens (and some
others not yet recognized), we would not be
too surprised if the specific nonresponsiveness
that can be induced by the combination of one
blood transfusion, immunosuppression, and
matching for one HLA-DR determinant will
lead to very good graft survival. If, on the
other hand, the recipient has been immunized
against one or more of these determinants,
matching for them as well will be obligatory.
In conclusion, we think it permissible to say
that the future has never looked so bright. DR
matching was developed to select DR-identi-
cal combinations. The fact that one DR-
matched grafts do so well is an unexpected
bonus. It provides us also with an answer to
the embarassing question of why grafts
mismatched for several HLA-A and Β anti-
gens not infrequently do so well. This unpre-
dicted finding teaches us modesty and indi-
cates shortcomings of our experimental proto-
cols. It is reassuring that it also shows us that
one can go the right way (in this case develop
DR typing) for the wrong reason (the
assumption that only DR-identical matches
would be good enough)
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